| 產(chǎn)品編號(hào) | bs-11611R-PE-Cy7 |
| 英文名稱(chēng) | Rabbit Anti-CDK5R1/p35/PE-Cy7 Conjugated antibody |
| 中文名稱(chēng) | PE-Cy7標(biāo)記的細(xì)胞周期蛋白依賴(lài)性激酶5激活因子1抗體 |
| 別 名 | CD5R1_HUMAN; CDK 5R1; CDK5 activator 1; CDK5P35; CDK5R; CDK5R1; Cyclin dependent kinase 5 activator 1; Cyclin dependent kinase 5 regulatory subunit 1; Cyclin-dependent kinase 5 activator 1; Cyclin-dependent kinase 5 regulatory subunit 1; MGC33831; NCK 5A; NCK5A; Neuronal CDK5 activator; p23; p25; p25 included; p35; p35nck5a; Regulatory partner for CDK5 kinase; Tau protein kinase II 23 kDa subunit; Tau protein kinase II 23kDa subunit; TPKII regulatory subunit. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢(xún)價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 研究領(lǐng)域 | 細(xì)胞生物 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 細(xì)胞周期蛋白 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 表觀遺傳學(xué) |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, Sheep, ) |
| 產(chǎn)品應(yīng)用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 34kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human p35 (219-307aa) |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The protein encoded by this gene (p35) is a neuron-specific activator of cyclin-dependent kinase 5 (CDK5); the activation of CDK5 is required for proper development of the central nervous system. The p35 form of this protein is proteolytically cleaved by calpain, generating a p25 form. The cleavage of p35 into p25 results in relocalization of the protein from the cell periphery to nuclear and perinuclear regions. P25 deregulates CDK5 activity by prolonging its activation and changing its cellular location. The p25 form accumulates in the brain neurons of patients with Alzheimer's disease. This accumulation correlates with an increase in CDK5 kinase activity, and may lead to aberrantly phosphorylated forms of the microtubule-associated protein tau, which contributes to Alzheimer's disease. [provided by RefSeq, Jul 2008] Function: p35 is a neuron specific activator of CDK5. The complex p35/CDK5 is required for neurite outgrowth and cortical lamination. Activator of TPKII. Subunit: Heterodimer composed of a catalytic subunit CDK5 and a regulatory subunit CDK5R1 (p25) and macromolecular complex composed of at least CDK5, CDK5R1 (p35) and CDK5RAP1 or CDK5RAP2 or CDK5RAP3. Only the heterodimer shows kinase activity. Interacts with EPHA4 and NGEF; may mediate the activation of NGEF by EPHA4 (By similarity). Interacts with RASGRF2. [INTERACTION] Q6ZMQ8-1:AATK; NbExp=2; IntAct=EBI-746189, EBI-2008436; Q6ZMQ8-2:AATK; NbExp=6; IntAct=EBI-746189, EBI-2008441; Q00535:CDK5; NbExp=5; IntAct=EBI-746189, EBI-1041567. [SUBCELLULAR LOCATION] Cyclin-dependent kinase 5 activator 1, p35: Cell membrane; Lipid-anchor; Cytoplasmic side (Probable). Note=In the primary cortical neurons, p35 is present in the peripheries and nerve terminals. Subcellular Location: Cell membrane. In the primary cortical neurons, p35 is present in the peripheries and nerve terminals and Nucleus. Cytoplasm > perinuclear region. The conversion of p35 to p25 relocalizes the protein from the cell periphery to the cytoplasm, in nuclear and perinuclear regions. In the primary cortical neurons, p25 is primarily concentrated in the cell soma and is largely absent from neurites. Tissue Specificity: Brain and neuron specific. Post-translational modifications: The p35 form is proteolytically cleaved by calpain, giving rise to the p25 form. P35 has a 5 to 10 fold shorter half-life compared to p25. The conversion results in deregulation of the CDK5 kinase: p25/CDK5 kinase displays an increased and altered tau phosphorylation in comparison to the p35/CDK5 kinase in vivo. Probably myristoylated. The Gly-2-Ala mutant is absent of the cell periphery, suggesting that a proper myristoylation signal is essential for the proper distribution of p35. Similarity: Belongs to the cyclin-dependent kinase 5 activator family. Database links: Entrez Gene: 8851 Human Entrez Gene: 12569 Mouse Omim: 603460 Human SwissProt: Q15078 Human SwissProt: P61809 Mouse Unigene: 500015 Human Unigene: 142275 Mouse Unigene: 474282 Mouse Unigene: 11213 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
